Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | BID | P55957 | 4/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.45 |
| ▸ | BAK1 | Q16611 | 3/20 | 0.45 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.45 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.45 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.45 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL943234 | 0.93 | SLC28A3 (0.57) | SLC28A3PTPN1SLC5A1MAOBMCL1 | |
| SCHEMBL940441 | 0.88 | SLC28A3 (0.60) | SLC28A3PTPN1SLC5A1MCL1 | |
| SCHEMBL940116 | 0.78 | SLC28A3 (0.81) | SLC28A3PTPN1SLC5A1 | |
| SCHEMBL941047 | 0.78 | MAOB (0.53) | SLC28A3PTPN1SLC5A1MAOBMCL1 | |
| SCHEMBL28720616 | 0.78 | MAOB (0.54) | SLC28A3PTPN1SLC5A1MAOB | |
| SCHEMBL28254468 | 0.76 | MAOB (0.61) | SLC5A1MAOBMCL1 | |
| SCHEMBL27722633 | 0.76 | MAOB (0.61) | SLC5A1MAOBMCL1 | |
| SCHEMBL941361 | 0.76 | PPARG (0.53) | SLC28A3SLC5A1MAOBPPARGPPARA | |
| SCHEMBL941331 | 0.76 | PPARG (0.55) | SLC28A3MAOBPPARGPPARA | |
| SCHEMBL12610429 | 0.75 | SLC28A3 (0.55) | SLC28A3PTPN1SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110014141-A1 | TOPICAL AGENT FOR DERMATOLOGICAL USE | DSM IP ASSETS B.V. (NL) | 2011-01-20 | — | — | US | disclosed |
| EP-1859835-A2 | Topical agent for dermatological use containing 4-hydroxyphenyl-alpha-D-glucopyranoside | PENTAPHARM Ltd. (CH) | 2007-11-28 | — | — | EP | disclosed |
| US-20030198610-A1 | Topical agent for dermatological use | DSM IP ASSETS B.V. (NL) | 2003-10-23 | — | — | US | disclosed |
| EP-1289489-A2 | TOPICAL AGENT FOR DERMATOLOGICAL USE CONTAINING 4-HYDROXYPHENYL-ALPHA-D-GLUCOPYRANOSIDE | PENTAPHARM Ltd. (CH) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001091715-A2 | TOPICAL AGENT FOR DERMATOLOGICAL USE CONTAINING 4-HYDROXYPHENYL-ALPHA-D-GLUCOPYRANOSIDE | PENTAPHARM LTD. (CH) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014141-A1 | TOPICAL AGENT FOR DERMATOLOGICAL USE | GALE, ALPP, UGGT1 | SLC28A3 2245/4885PTPN1 2641/4885SLC5A1 1371/4885 |
| US-20030198610-A1 | Topical agent for dermatological use | GALE, UGGT1, UGDH | SLC28A3 2040/4885PTPN1 2683/4885SLC5A1 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.